by Bruce Sylvester: Among patients with metastatic hormone-sensitive prostate cancer, chemotherapy with docetaxel at the start of androgen deprivation therapy (ADT) has resulted in an increased survival of… read more.
by Bruce Sylvester: Oral contraceptive use appears to provide long-term protection against endometrial cancer, researchers reported on August 4, 2015 in The Lancet Oncology.
Daily bathing of pediatric patients with disposable cloths containing 2 percent chlorhexidine gluconate (CHG) reduced central line-associated bloodstream infections (CLABSIs) by 59 percent and saved approximately $300,000 in… read more.
by Bruce Sylvester: Rociletinib, an investigative therapy for treatment resistant EGFR-mutation driven lung tumors, shows activity against the most common resistance mutation, and it significantly improves clinical outcomes.
by Gary Finnegan: People with terminal cancer often require palliative care in the late stages of their lives. This branch of medicine has long been lauded for the… read more.
by Bruce Sylvester: Investigators from the phase III PALOMA-3 trial report that treatment with the recently FDA-approved drug palbociclib more than doubled the time to cancer recurrence among… read more.
by Bruce Sylvester: Treatment of advanced melanoma with a combination of nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.
by Bruce Sylvester: Anastrozole is significantly more effective than tamoxifen in preventing cancer recurrence after lumpectomy and radiation therapy in postmenopausal women, age 60 or younger with DCIS… read more.
by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.
Results highlight importance of pre-test counselling for at-risk patient populations. Some at-risk patients opted out of comprehensive cancer gene screening when presented with the opportunity to be tested… read more.
by Bruce Sylvester: Patients with metastatic melanoma treated with dual sargramostim/ipilimumab rather than ipilimumab alone have achieved longer overall survival and lower toxicity, but no difference in progression-free… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
